Agilent (A) Form 144: Insider Plans to Sell 2,000 Shares ($249,760)
Form 144 filing for Agilent Technologies, Inc. (A): The filer notified an intended sale of 2,000 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $249,760.00, with an approximate sale date of 09/02/2025 on the NYSE.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Form 144 filing for Agilent Technologies, Inc. (A): The filer notified an intended sale of 2,000 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $249,760.00, with an approximate sale date of 09/02/2025 on the NYSE. The schedule lists the acquisition of smaller blocks of restricted stock that vested between 11/14/2023 and 05/19/2024 (totaling 2,000 shares listed). The filing also discloses two prior sales by the same person in 07/2025 (1,508 shares) and 08/2025 (2,000 shares) with gross proceeds shown.
Insights
TL;DR: Routine insider sale notice showing modest planned disposition and recent past sales; not a company earnings or operational disclosure.
The Form 144 documents a proposed sale of 2,000 Agilent shares valued at $249,760 via Fidelity, and lists the original acquisitions as restricted stock vesting events in late 2023 and mid-2024. It also records two recent sales in July and August 2025 totaling 3,508 shares with reported gross proceeds. From a trading disclosure perspective this is a compliance filing that notifies the market of intended insider liquidity activity; it does not provide operational or financial performance data.
TL;DR: Filing fulfills Rule 144 disclosure for insider sales; shows vesting-based holdings being monetized but contains no governance changes.
The submission lists vesting as the origin of the securities being sold, indicating these shares were received as compensation. The filer attests to lack of undisclosed material information. There is no indication of management departure, transaction with related parties, or a 10b5-1 plan date provided. As a governance disclosure, it is routine and informational.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 for Agilent Technologies (A) report?
Which broker will execute the proposed sale?
Does the filing state any 10b5-1 trading plan adoption date?
AI-generated analysis. How Rhea-AI works. Not financial advice.